NCT02954822 - Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2016

Primary Completion Date

January 25, 2017

Study Completion Date

August 9, 2017

Conditions

Type2 Diabetes

Interventions

DRUG

Evogliptin→Evogliptin+Glimepiride→Glimepiride

"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"

DRUG

Glimepiride→Evogliptin→Evogliptin+Glimepiride

After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.

Trial Locations (1)

03080

Clinical Trials Center, Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY